John Leonard

In this discussion, esteemed lymphoma expert Dr. John Leonard from NYU Langone Cancer Center delves into the complexities of treating diffuse large B-cell lymphoma (DLBCL). He highlights the evolving management strategies, particularly the promising Pola-R-CHP regimen and its implications for Stage 1 and 2 diseases. Dr. Leonard also explores the emerging options for relapsed cases, including CAR-T therapy and bispecific antibodies, while emphasizing the importance of tailoring treatments for various patient profiles.